This study aims to understand patient decision-making in Axial Spondyloarthritis (axSpA) and explore how decision-making, treatment satisfaction, and biologic disease modifying antirheumatic drugs (bDMARDs) may be related.
Read More
This virtual, longitudinal study explores the different patient-reported outcomes (PROs) that patients with rheumatic and musculoskeletal diseases consider important for their disease management.
There is limited information regarding treatment experience of patients with axial spondyloarthritis/ ankylosing spondylitis (axSpA/AS) receiving biological disease-modifying antirheumatic drugs (bDMARDs). This study shares the experience of 128 patients currently taking a bDMARD therapy for axSpA or AS.
In this study, Ogdie et al. report descriptives of patients diagnosed with Ankylosing Spondylitis (AS) in the United States. Among 235 respondents, women experienced worse disease severity. The most common symptoms that led to seeking medical care included back pain, joint pain, stiffness, and fatigue. The most commonly reported misdiagnoses were back problems, psychosomatic issues, and sciatica. The results highlight differences between men and women in initial symptom presentation, misdiagnoses, time to diagnosis of AS, and the impact of AS on work and relationships.
In this study, Ogdie et al. report descriptives of patients diagnosed with Ankylosing Spondylitis (AS) in the United States. Among 235 respondents, women experienced worse disease severity. The most common symptoms that led to seeking medical care included back pain, joint pain, stiffness, and fatigue. The most commonly reported misdiagnoses were back problems, psychosomatic issues, and sciatica. The results highlight differences between men and women in initial symptom presentation, misdiagnoses, time to diagnosis of AS, and the impact of AS on work and relationships.
